Theravance Biopharma share price

Theravance Biopharma, Inc.'s share price was $17.03 at the close on 23 September 2026. It has been moving sideways for 10 weeks. That is 0.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $20, and at that close it sat 50% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Theravance Biopharma, Inc. is in stage 1. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 10 years the share price moved −27% while the S&P 500 moved +263%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Theravance Biopharma, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Theravance Biopharma is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Theravance Biopharma, Inc. posted a net loss of $5.9 M in the Jun 2026 quarter. Full-year FY25 profit was $106 M. That loss is 28.5% of the quarter's revenue. The same quarter a year earlier earned $54.8 M. 9 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Jun 2026 profit was −$5.9 M, −110.8% on a year earlier.

Theravance Biopharma, Inc. reported $20.7 M of revenue in the Jun 2026 quarter, −20.9% on the same quarter a year earlier. Over 4 years it has grown 18.1% a year on average. The last full year, FY25, came in at $107 M. The last four reported quarters add to $104 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $107 M, +66.9% on the year before.

Recent pace: the last four quarters grew +39.3% on average, against 18.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +35.1%, against +29.7% a year over the last 8 quarters (accelerating).

Theravance Biopharma, Inc.'s operating margin was 8.9% in the Jun 2026 quarter, 19.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between −429.6% and −3.4%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +19.3 percentage points on the year while gross margin changed +17.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 2 years, 5% of Theravance Biopharma, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $239 M of operating cash against $106 M of profit. After $42.0 K of spending on assets, $238 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Theravance Biopharma, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.9 M on assets over the last 3 years. Averaged over those years that is 0.9% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $2.9 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Theravance Biopharma, Inc.'s P/E is 16.3×, near the high end of its own history: higher than 71% of past readings. Its usual P/E (the middle reading) is 1.0×, over 4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Where the price move came from: over 3 years the price moved +23.2% a year; about −55.3% a year came from earnings growth and about +78.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Theravance Biopharma, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Theravance Biopharma, Inc. earned a ROE of 36% in FY25. That is up from a low of −32% in FY24. Its return on capital used (ROIC) is 9.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a 98.5% net margin and 0.22× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a 98.5% net margin × 0.22× asset turnover × 1.64× leverage (assets divided by equity) ≈ 35.5% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: −3.7% − 5.5% = −9.2 percentage points. The 5.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.